Open Orphan distribution in specie shares and in particular some people had been concerned that they were unable to trade them.
Open Orphan PLC (ORPH.L) Imutex Vaccine Phase I Study Results
mutex to present positive Phase I clinical study results for AGS-v PLUS mosquito vaccine candidate AGS-v PLUS mosquito vaccine candidate shows favourable safety, tolerability, and immunogenicity results
Open Orphan PLC (ORPH.L) £5.1m RSV Human Challenge Study Contract Win
Open Orphan plc (AIM: ORPH), a rapidly growing specialist contract research organisation (CRO) and world leader in vaccine and antiviral testing using human challenge clinical trials , announces that hVIVO
Open Orphan PLC (ORPH.L) £1.5m Contract renewal for Venn Life Sciences
£1.5m Contract renewal for Venn Life Sciences with a major global pharmaceutical client
Open Orphan PLC (ORPH.L) Directorate Change
Open Orphan plc (AIM: ORPH), a rapidly growing specialist contract research organisation (CRO) and world leader in vaccine and antiviral testing using human challenge clinical trials , announces the appointment
How one company is testing vaccines through intentional infection
Open Orphan Executive Chairman Cathal Friel joins Yahoo Finance Live to discuss how his company is testing vaccines through intentional infection.
Open Orphan PLC (ORPH.L) £5.7m Influenza human challenge study contract win
Open Orphan plc (AIM: ORPH), a rapidly growing specialist clinical research organisation (CRO) and world leader in vaccine and antiviral testing using human challenge clinical trials , announces that hVIVO
Open Orphan PLC (ORPH.L) Notice of Interim Results
Open Orphan plc (AIM: ORPH), a rapidly growing specialist contract research organisation (CRO) and world leader in vaccine and antiviral testing using human challenge clinical trials , announces that its
Open Orphan PLC (ORPH.L) Positive results from RSV Human Challenge Study
RSV Human Challenge Study conducted by hVIVO yields positive results
Open Orphan PLC (ORPH.L) £8.1m Asthma Human Challenge Study Contract Win
Open Orphan plc (AIM: ORPH), a rapidly growing specialist contract research organisation (CRO) and world leader in vaccine and antiviral testing using human challenge clinical trials , announces that hVIVO
Open Orphan PLC (ORPH.L) Malaria Human Challenge Model
Development of Controlled Human Malaria Infection Human Challenge Study hVIVO to assist in the advancement of antimalarial drug and vaccine candidates from November 2021